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Abstract
Epithelial to mesenchymal transition (EMT) is a developmental event that is hijacked in some diseases such as fibrosis and
cancer. In cancer, EMT has been linked to increased invasion and metastasis and is generally associated with a poor prognosis. In
this study, we have compared phenotypic and functional differences between two isogenic cell lines with an EMT profile:
D492M and D492HER2 that are both derived from D492, a breast epithelial cell line with stem cell properties. D492M is
non-tumorigenic while D492HER2 is tumorigenic. Thus, the aim of this study was to analyze the expression profile of these cell
lines, identify potential oncogenes, and evaluate their effects on cellular phenotype. We performed transcriptome and secretome
analyses of D492M and D492HER2 and verified expression of selected genes at the RNA and protein level. One candidate,
YKL-40 (also known as CHI3L1), was selected for further studies due to its differential expression between D492M and
D492HER2, being considerably higher in D492HER2. YKL-40 has been linked to chronic inflammation diseases and cancer,
yet its function is not fully understood. Knock-down experiments of YKL-40 in D492HER2 resulted in reduced migration and
invasion as well as reduced ability to induce angiogenesis in an in vitro assay, plus changes in the EMT-phenotype. In summary,
our data suggest that YKL-40 may provide D492HER2 with increased aggressiveness, supporting cancer progression and
facilitating angiogenesis.
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Introduction
Epithelial to mesenchymal transition (EMT) is a developmen-
tal process that describes the plasticity of epithelial cells to
change phenotype from compact adherent epithelium to
mesenchymal-like cells that have lost their polarity and cell-
cell adherence (Thiery et al. 2009). This is an important event
in normal development, during gastrulation, neural crest for-
mation, and wound healing, but also takes place in malignant
processes like fibrosis and cancer (Thiery et al. 2009; Nieto
2013). In cancer, EMT is associated with increased aggres-
siveness and it is believed to be necessary for migration and
invasion of cancer cells for the initial steps in the metastatic
processes (Thiery et al. 2009).
The EMT process is accompanied by increased expression
of mesenchymal markers such as vimentin, N-cadherin, α-
smooth muscle actin, fibronectin, and/or Axl, as well as de-
creased or absent expression of epithelial markers like
cytokeratins, yet the most referenced change in EMT is the loss
of E-cadherin (Peinado et al. 2007; Gjerdrum et al. 2010). EMT
is known to be induced by a number of factors. It can take place
due to intrinsic factors such as genetic mutations or epigenetic
changes or extrinsic factors like hypoxia or inflammation that
stimulate the release of signals from the stroma (Yang et al.
2008; Kalluri and Weinberg 2009; Polyak and Weinberg
2009). Transforming growth factor beta (TGF-β) has been
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shown to be a powerful inducer of EMT in a number of cell
types (Kasai et al. 2005; Willis and Borok 2007; Kalluri and
Weinberg 2009). Tyrosine kinase receptors and their ligands
like EGF, PDGF, FGF, and HGF have also been shown to
induce EMT (Kalluri andWeinberg 2009). Recently, regulatory
functions carried out by non-coding RNAs have attracted the
attention of researchers. Downregulation of miRNAs, especial-
ly members of the miR-200 family, miR-203, and miR-205,
have been linked to EMT (Wiklund et al. 2010; Moes et al.
2012; DeCastro et al. 2013; Hilmarsdottir et al. 2014, 2015). In
epithelial cells, the expression of these miRs is high but is
commonly reduced or absent during EMT. Interestingly, rescue
of these miRs can revert the EMT phenotype in the process
mesenchymal to epithelial transition (MET) (Burk et al. 2008;
Korpal et al. 2008; Hilmarsdottir et al. 2014). Furthermore,
EMT in cells is often accompanied by increased ability to mi-
grate and invade, as well as increased resistance to apoptosis
(Thiery et al. 2009). For this reason, EMT has been related to
aggressiveness and metastasis in cancer (Thiery 2002; Nieto
2013; Tan et al. 2014). The concept of cancer stem cells
(CSCs) has also been linked to EMT, where EMT is an integral
part of CSC plasticity and survival (Mani et al. 2008). Like
somatic stem cells, CSCs have the capability to self-renew
and their EMT phenotype is believed to be protective against
external damages, which could lead to resistance to cancer ther-
apies (Al-Hajj et al. 2003; Stingl 2006). In addition, CSCs as a
cell population could be the cells responsible for the dissemi-
nation of cancer cells and the heterogeneity evidenced in me-
tastasis (Brabletz 2012). Therefore, it is vital to elucidate the
role of CSCs in cancer progression in order to improve efficient
treatments and targeted therapy.
In breast cancer, the subtype basal-like breast cancer
(BLBC) is identified as having the most undifferentiated cells
and heterogeneity, which has been linked to CSCs and inter-
estingly has a higher incidence of EMT (Mani et al. 2008;
Morel et al. 2008; Sarrio et al. 2008). However, EMT is not
exclusively found in this subtype. In luminal and HER2 breast
cancers, there is an EMT-derived phenotype, although at a
lower percentage (Yu et al. 2013; Tan et al. 2014).
Resistance to drugs in breast cancer may be associated with
EMT-phenotype and heterogeneity of cells in the tumor. It is
important to note that states of EMTare not merely defined as
completely epithelial or mesenchymal; there are intermediate
states of EMT that provide plasticity and advantages to cells to
adapt to their microenvironment. This program is referred as
partial-EMT (p-EMT) (Huang et al. 2013; Nieto 2013; Tam
and Weinberg 2013; Yu et al. 2013).
The epithelial cells that reside in the breast gland are under
continuous remodeling due to hormonal cycling and interac-
tions with the surrounding stroma. This crosstalk is required in
normal development and differentiation, and is utilized by
tumor cells during cancer progression. Resident fibroblasts
and macrophages in the stroma are able to produce growth
Table 1. List of primers used in this study. List of gene IDs for all target
genes used and their corresponding primer IDs and supplier
Primers Cat. number Company
miR-200c No. YP00204482 Qiagen
miR-203 No. 205914 Exiqon

















Table 2. List of antibodies used
in this study. List of primary
antibodies (protein IDs, dilution,
company, and order IDs) for
western blotting and IF staining
for candidate proteins
Antibodies Assay Cat. number Company Dilution
Actin WB ab3280 Abcam 1:5000
Axl IF CS no. 8661 Cell Signaling 1:100
CK14 WB ab15461 Abcam 1:1000
CK19 IF ab7754 Abcam 1:100
E-cadherin WB 610182 BD Transduction Labs 1:1000
Tubulin WB ab6046 Abcam 1:5000
Vimentin WB M0725 DAKO 1:1000
YKL-40 /CHI3L1 IF MABC196 Millipore 1:100
YKL-40 /CHI3L1 WB MABC196 Millipore 1:500
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factors and pro-inflammatory molecules, but also pro-
angiogenic molecules that support the creation of new blood
vessels. Fibroblasts not only interact with epithelial cells, they
also activate the action of immune cells like macrophages and
promote angiogenesis by cell communication with endothelial
cells. The vascular endothelial growth factor (VEGF) and
TGF-β are secreted by fibroblasts and macrophages, and they
are able to stimulate angiogenesis. TGF-β induces the expres-
sion of VEGF that is secreted to the ECM and stimulates
endothelial cells to initiate angiogenesis (Relf et al. 1997;
Carmeliet and Jain 2000).
There is also direct interaction between epithelial cells and
endothelial cells. The vascular niche plays an important role in
transporting oxygen and nutrients and releasing signals for its
correct morphogenesis and development. Indeed, it has also
been observed that endothelial cells increase growth and
branching morphogenesis of breast epithelium (Shekhar
et al. 2000; Sigurdsson et al. 2006; Ingthorsson et al. 2010)
and induce EMT (Sigurdsson et al. 2011). In the context of
cancer, the high proliferation rate of tumor cells can lead to a
reduction in oxygen concentration resulting in acidification of
the surrounding stroma. In order to survive, cancer cells are
able to secrete signals that induce angiogenesis, such as VEGF
(Hanahan and Weinberg 2011). Receptors on endothelial
cells, such as VEGFR2, are induced to trigger activation of
the transcriptional machinery of angiogenesis that involves
the hypoxic inducible factor 1 (HIF1) and other factors like
nuclear factor κB (NF-κB) (Vegran et al. 2011; Sonveaux
et al. 2012). The increase in angiogenesis ensures oxygen
and a nutrient supply and therefore results in a worse progno-
sis of the cancer, making it an important factor to study.
D492 is a breast progenitor epithelial cell line that was
established by immortalization of a suprabasal subpopulation of
breast tissue from a healthy donor (Gudjonsson et al. 2002). As
reviewed in Briem et al. (2019), D492 can generate both luminal
and myoepithelial cells, and in 3D culture forms branching ter-
minal ductal lobular units (TDLU) like structures (Briem et al.
2019). We have previously demonstrated that when D492 is co-
culturedwith breast endothelial cells (BRENCs), a subpopulation
of cells undergoes EMT. One such subpopulation was isolated,
giving rise to the D492M cell line, which has a fixed mesenchy-
mal phenotype (Sigurdsson et al. 2011). In addition, we have
shown that D492 cells with forced overexpression of the HER2
oncogene (D492HER2) have lost their epithelial phenotype and
gained a mesenchymal one (Ingthorsson et al. 2015).
In this study, we have compared functional and phenotypic
differences betweenD492MandD492HER2.We show here that
D492HER2 proliferates, migrates, and invades faster than
D492M. Furthermore, glucose metabolism is more dependent
on glycolysis than oxidative phosphorylation in D492HER2.
The comparative analysis of transcriptome revealed that a glyco-
protein, YKL-40, also known as CHI3L1, is highly upregulated
in D492HER2 and may contribute to the differences in tumori-
genicity between the cell lines. YKL-40 has previously been
linked to chronic inflammation diseases and cancer (Libreros
et al. 2012; Jefri et al. 2015; Libreros and Iragavarapu-
Charyulu 2015; Cohen et al. 2017); however, its function is not
clearly understood yet. Functional studies using knockdown of
YKL-40, recombinant protein, and overexpression experiments
reveal that YKL-40 influences migration, invasion, and angio-
genesis and induces changes in the EMT phenotype.
Material and Methods
Cell culture (2D and 3D) The main cell lines used in this pro-
ject were D492 (Gudjonsson et al. 2002) and its EMT-
phenotype-derived cell sublines D492M (Sigurdsson et al.
2011) and D492HER2 (Ingthorsson et al. 2015). For mono-
layer culture, flasks or plates were pre-coated with collagen I
(2.2%) (no. 5005-B, Advanced BioMatrix, Carlsbad, CA).
The medium used for culturing the cell lines was H14
(Blaschke et al. 1994), an enriched serum-free medium based
on DMEM:F12 in which growth factors are added (insulin,
Table 3. siRNAs used for transient YKL-40 knockdown. Catalog numbers of siRNAs used as negative control and transient knock-down of YKL-40
siRNAs Product name Cat. number Company
Neg Ctrl siRNA Silencer® Select Negative Control No. 1 siRNA 4390843 ThermoFisher Scientific
YKL-40 siRNA 1 Silencer® Select CHI3L1 siRNA 1 AM16708 (ID 119124) ThermoFisher Scientific
YKL-40 siRNA 2 Silencer® Select CHI3L1 siRNA 2 AM16708 (ID 119126) ThermoFisher Scientific
Table 4. gRNAs used for generating stable cell lines. Names and sequences of gRNAs used to either knockdown or overexpress YKL-40
gRNAs Sequence Action Company
YKL-40/CHI3L1 KD CCGCCATTTCTGCGCACCCA Knockdown
YKL-40/CHI3L1 SAM OV 1 AGTTTTGAAAACTTTGGGTC Overexpress Genscript
YKL-40/CHI3L1 SAM OV 2 CTGCCAGCAGAAGAGCCACT Overexpress Genscript
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transferrin, EGF, sodium selenite (NaSel), estradiol, hydrocor-
tisone, prolactin).
Human umbilical vein endothelial cells (HUVECs) were
isolated from umbilical cords obtained from Landspitali
University Hospital, Reykjavik, Iceland, with informed con-
sent and approved by the Landspitali ethical committee (No.
35/2013). HUVECs were cultured in EGM2 + 5% FBS (no.
CC-3162, Lonza).
In 3D cultures, cells were cultured in 300 μL of Matrigel
(no. 354230, Corning, Corning, NY) per well, in 24-well
plates (no. 353047, Corning, Corning, NY). In monoculture,
20,000 cells were embedded in reconstituted basement mem-
brane, rBM, purchased as Matrigel (Corning no. 354230),
with 500 μL of H14 media on top, while in co-cultures, 500
cells of D492 or its sublines were co-cultured with 150,000–
200,000 HUVECs, embedded in Matrigel, with 500 μL of
EGM2 + 5% FBS media on top.
Gene expression levels by qRT-PCR Total RNA was isolated
with cold Tri-Reagent reagent (no. AM9738, Life
Technologies, Carlsbad, CA). RNA precipitation was done using
isopropanol and centrifugation at 14,000 rpm for 20 min.
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Afterwards, RNAwaswashedwith ethanol two times. The RNA
pellet was diluted in RNAse free water. Concentration of RNA
was measured using a NanoDrop® ND-1000 UV/Vis-
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
For cDNA synthesis, SuperScript IV (no. 18090-200, Thermo
Fisher Scientific) and random hexamer primers were used.
To quantify the expression level of genes, TaqMan (no.
M3004L, NEB) or SYBR Green (no. M3003L, NEB) chem-
istries were used to detect gene expression. Comparative Ct
values were determined using an ABI 7500 instrument
(Applied Biosystems, Foster City, CA). All used primers are
listed in Table 1. GAPDH was used as the reference gene.
Expression levels of miRNAs by qRT-PCR Total RNA was ex-
tracted with Tri-Reagent (no. AM9738, Thermo Fisher
Scientific). The RNA was reverse transcribed using
miRCURY LNA RT Kit (no. 339340, Qiagen, Hilden,
Germany) for cDNA synthesis reactions. Quantitative RT-
PCR analysis of miRNAs was performed using miRCURY
LNA SYBR Green PCR Kit (no. 339346, Qiagen). Relative
expression was calculated with the 2ΔΔCt method. All used
primers are listed in Table 1. Normalization was done with
U6 (no. 203907, Exiqon, Vedbaek, Denmark).
Protein levels by Western Blot (WB) Protein isolation was
done using RIPA buffer, and the concentration was mea-
sured by the colorimetric Bradford method. Equal amount
of protein was loaded for each sample (5 μg) in precast
NuPAGE 10% Bis-Tris gels (Invitrogen, Carlsbad, CA).
Proteins were detected using IRDye secondary antibodies
on an Odyssey imaging system (Li-Cor Biosciences,
Lincoln, NE). Loading controls actin or tubulin were used
for quantification. Antibodies used for WB are listed in
Table 2.
Immunostaining Immunofluorescence (IF) was used to de-
tect proteins and visualize their subcellular location. Cells
were fixed with 3.7% paraformaldehyde (PFA) and
permeabilized with 0.1% Triton X-100. Blocking with
FBS was done prior to incubation with primary antibod-
ies. Incubation was done overnight at 4°C and followed
by incubation of secondary antibodies conjugated to fluo-
rochromes Alexa Fluor-488, Fluor-546, or Fluor-647 for
1 h at room temperature. For nuclei staining, DAPI was
used. Imaging was done using an EVOS FL Auto 2 Cell
Imaging System (Thermo Fisher Scientific) or FV1200
Olympus inverted confocal microscope. Antibodies used
for IF are listed in Table 2.
Transcriptome data analysis and classification Total RNA se-
quence profiles for D492, D492M, and D492HER2 were ob-
tained from normal cell cultures and treated following the
protocol detailed in Halldorsson et al. (2017).
Differentially expressed genes between cell lines were fur-
ther classified into categories to see the biological processes
that were enriched. Using a differential range from two fold
change, genes were analyzed by the PANTHER analysis da-
tabase (www.pantherdb.org) following instructions of Mi
et al. (2013).
Secretome data analysis For mass spectrometry, D492 lines
were grown in T175 flasks (no. 353112, Corning) and condi-
tioned medium (CM) was collected, concentrated for 55 min
using EMD Millipore Amicon™ Ultra-15 Centrifugal Filter
Units (no. UFC900324, Merck Millipore, Darmstadt,
Germany) followed by buffer exchange to 100 mM TRIS/HCl
buffer. Triplicate samples were stored at − 80°C. Label-free rela-
tive protein quantification by nLCMS/MS after trypsin digestion
was performed at the FingerPrints Proteomics Facility,
University of Dundee, Dundee, UK and raw data were analyzed
using MaxQuant software (version 1.6.2.1). Quantitative and
statistical analyses were performed using XLStat (version
2018.1). Data were P value corrected (significance level 0.05)
Figure 1. Phenotypic and functional characterization of D492M and
D492HER2 cell lines. (a) D492M and D492HER2 are isogenic EMT-
derived sublines of D492, a breast epithelial cell line with progenitor
properties, which in 3D cell culture forms branching structures, resem-
bling the TDLUs of the breast. D492M and D492HER2 were generated
when D492 underwent endothelial-induced and oncogene (HER2)-in-
duced EMT, respectively. D492M and D492HER2 show similar EMT-
phenotype in 2D, but in 3D, D492M generate spindle-like colonies
whereas D492HER2 generate spindle-like and grape-like colonies.
D492M and D492HER2 also differ in their ability to generate tumors,
as only D492HER2 is able to form tumors. Scale bar = 200 μm. (b)
D492M and D492HER2 have lost expression of epithelial markers (E-
cadherin, cytokeratin-14, and cytokeratin-19) and gained expression of
mesenchymal markers (Axl and vimentin) as shown by western blotting
and immunofluorescence. Scale bar = 100 μm. (c) D492M and
D492HER2 show reduction in the expression of epithelial microRNAs
such as miR-200c, miR-203, and miR-205 compared to D492. The low-
est levels of expression are found in D492M (mean ± SD, n = 2). (d) In
transwell migration and invasion assays, D492HER2 has an increased
ability to migrate and invade compared to D492 and D492M. Results
are shown as average number of cells per field (mean ± SEM, n = 3).
One-way analysis of variance (ANOVA) and Dunnett’s multiple compar-
ison test were used to test significance (*p ≤ 0.05, **p ≤ 0.01). (e)
D492HER2 cells proliferate at a higher rate than D492 and D492M cells
as shown by staining with crystal violet. Results are shown as average of
four replicates (mean ± SD). Statistical significance was assessed using
multiple t tests (one per row) (**p ≤ 0.01, ****p ≤ 0.0001). (f)
Furthermore, increased proliferation rate of D492HER2 compared to
D492 and D492M cells was demonstrated using PrestoBlue™ Cell
Viability reagent. Results are shown as average of eight replicates nor-
malized to D492 (mean ± SD). One-way analysis of variance (ANOVA)
and Dunnett’s multiple comparison test were used to test significance
(****p ≤ 0.0001). (g) In addition, D492HER2 cells are more susceptible
to chemically induced apoptosis as compared to D492 and D492M cells.
Caspase 3/7 luciferase activity was measured by luminescence and nor-
malized to D492 (mean ± SEM, n = 2). Significance was assessed with
one-way analysis of variance (ANOVA) and Dunnett’s multiple compar-
ison test (*p ≤ 0.05).
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and sorted based on ≥ 2-fold higher secretion (LFQ intensity) by
D492HER2 compared to D492M.
Migration and invasion assays Migration and invasion assays
were done in 24-well plates with transwell filter inserts (no.
353097, Corning) of 8 μm size pore diameter. Transwell in-
serts in the migration assay were pre-coated with collagen I
(2.2%) and in the invasion assay; they were pre-coated with
Matrigel diluted 1:10 in H14 media. Fifty thousand cells/
transwell were seeded on the upper chamber in H14 media.
In the bottom chamber, H14was supplementedwith 10% FBS
as a chemoattractant. A cotton swab was used to remove non-
migrated and non-invaded cells after 24 h and after 48 h, re-
spectively. Thereafter, cells were fixed with 3.7% PFA and
Figure 2. YKL-40 is enriched in D492HER2. a The analysis of
transcriptome data comparing D492M and D492HER2 revealed more
than 3000 transcripts differently expressed (more than two fold). YKL-
40 (or CHI3L1) is more highly expressed in D492HER2 compared to
D492M. b Classification of genes in biological processes shows an en-
richment in D492HER2 compared to D492M in D-aspartate transport,
inflammatory response, cell chemotaxis, cytokine-mediated signaling
pathway, regulation of neurotransmitter levels, cellular response to
cytokine stimulus, organic anion transport, cell proliferation, and defense
response. YKL-40 is involved in the processes that require interaction
with the stroma: inflammatory response, cell chemotaxis, cellular re-
sponse to cytokine stimulus, and defense response (marked with yellow).
c Mass spectrometry analysis of secreted proteins in CM revealed that
YKL-40 is enriched in the secretome of D492HER2 compared to D492M
(p value = 0.01).
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stained with crystal violet (10%) or DAPI (1:5000 dilution)
for 30 min. Three random pictures were taken per well and the
number of cells was quantified. For DAPI-stained samples,
images were converted to 8-bit in ImageJ (version 2.0.0),
threshold-adjusted, and binary-converted and migratory/
invasive cells were counted using the analyze particles
function.
Proliferation assay Proliferation of cells was determined by
seeding 10,000 cells/well in triplicate in 24-well plates in H14
(D492 cell lines) or EGM5 (HUVECS). Every day (2 d for
HUVECs), cells were fixed and stained with crystal violet
(10%). Crystal violet was diluted with acetic acid and the OD
was measured at 570 nmwavelength. Alternatively, cell viability
was assessed using PrestoBlue™ Cell Viability Reagent
(ThermoFisher Scientific, Waltham, MA). Cells were seeded in
H14 media in a 96-well plate at a density of 3000 cells/well and
cultured for 4 d. PrestoBlue was added (1/10th of the total vol-
ume) to each well and incubated for 4 h, and absorbance was
read on a plate reader at 570 nm and 595 nm.
Apoptosis assay To quantify apoptosis, cleavage of caspase 3/7
was measured by a luciferase assay (ApoTox-GloTM Triplex
Assay, Promega, Madison, WI). Apoptosis was induced by in-
cubating cells with 10 μM camptothecin (CPT) for 24 h accord-
ing to the manufacturer’s protocol. After cellular lysis, luciferase
was measured with a microplate reader ModulusTM II (Turner
Biosystems, Sunnyvale, CA).
Glucose consumption and lactate production measurements
Glucose uptake was measured using Glucose Uptake-GloTM kit
(no. J1341, Promega) following the manufacturer’s protocol.
Briefly, the analogue of glucose, 2-deoxyglucose (2DG), was
added to the media and taken up by cells. When transported into
cells, 2DG is phosphorylated to 2-deoxyglucose 6-phosphate
(2DG6P) and further metabolization stimulates luciferase reac-
tions and luminescence was measured by the microplate reader
Modulus TM II (Turner Biosystems, Sunnyvale, CA).
Glucose consumption and lactate production were mea-
sured from the collected media when cells were in a high
confluency. Metabolites were measured at the Analyzer ma-
chine (ABL90 FLEX Analyzer, Radiometer) at the Blood
Bank of Landspitali (Reykjavik, Iceland).
Neutralization assay of YKL-40 protein A monoclonal anti-
body against YKL-40 (mAYKL40) (MABC196, Millipore)
was used to block the secretion of YKL-40 in D492HER2.
The antibody was diluted in fresh H14 medium at a con-
centration of 10 μg/mL. Medium from cells incubated for
24 h with mAYKL40 was collected, and medium from non-
treated D492HER2 cells was used as control. Conditioned
media (CM) were used for tube formation assays (described
below).
Tube formation assay on endothelial cells (angiogenesis assay
in vitro) To simulate angiogenesis in vitro, 10,000–12,000
HUVECs were seeded on top of 10 μL solidified rBM in a 96-
well angiogenesis plate (no. 89646, Ibidi). Controls included
HUVECs cultured in EGM5 media and a dilution of 1:1
EGM5 and conditioned media (CM). Recombinant YKL-40
protein (YKL-40r) (no. 11227H08H5, Thermo Fisher
Scientific, Waltham, MA) was added to the medium at a final
concentration of 100 ng/mL. After incubation overnight, the en-
dothelial network was imaged using the EVOS FL Auto 2 Cell
Imaging System. Analysis and quantification were done using
the Angiogenesis analyzer plug-in on ImageJ software (version
2.0.0).
Transient knockdown of YKL-40 by siRNA Pre-designed
siRNAs (Silencer® Select Pre-Designed, Validated and
Custom siRNA, Life Technologies) against YKL-40 were
used at a concentration of 10 nM inD492HER2 cells to down-
regulate YKL-40. First, cells were seeded on 6-well plate (no.
353046, Corning, Corning, NY) and after 24 h, cells were
transfected with the siRNA using chemical transfection with
Lipofectamine® RNAiMAX (no. 13778150, Life
Technologies, Carlsbad, CA). For each experiment, two dif-
ferent siRNAs against YKL-40 and a negative control siRNA
(no. 4390843, Life Technologies, Carlsbad, CA) were used.
The siRNAs are listed in Table 3. After 48 h, the knockdown
was confirmed by qRT-PCR and by WB.
Generation of stable cell line with knockdown of YKL-40 in
D492HER2 by CRISPR Specific gRNAs to knockdownYKL-40
were designed with the publicly available online ATUM
CRISPR tool (https://www.atum.bio/). Annealing of the
forward and reverse gRNA oligos was followed by ligation
with the backbone vector pMLM3636. High-efficiency com-
petent bacteria (no. C2987H, NEB) were transformed, and
confirmation of successful DNA insertion was done by colony
PCR. Plasmids were sequenced to confirm correct gRNA se-
quences. Transfection of D492HER2was done with four plas-
mid gRNAs and a plasmid with only a Cas9 cassette
(pST1374) using Lipofectamine® 3000 (Thermo Fisher).
The control cell line was generated by transfecting the cells
with only the Cas9 cassette. Selection of cells with insertion of
Cas9 was done using blasticidin. Knockdown of YKL-40 in
D492HER2 was confirmed by qRT-PCR and WB.
Subsequently, the cell line that gave the best efficiency of
knockdown was selected for further work. The sequence of
this gRNA is in Table 4. It should be noted that D492HER2 is
a cell line not suitable for single-cell cloning; therefore, a pool
of cells was used for confirmation of knockdown and further
experiments.
Generation of stable cell lines overexpressing YKL-40 in D492
and D492M by CRISPRa Overexpression of YKL-40 in D492
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and D492Mwas carried out using the modified CRISPR strat-
egy, called CRISPRa (Zhang et al. 2015). Two specific SAM
gRNAs for YKL-40 and one empty control were purchased
from Genscript containing zeomycin resistance cassettes. The
gRNA sequences are listed in Table 4. Transfection of
HEK293T cells was done to produce viral particles including
gRNAs. Viruses collected were used to infect D492 and
D492M cells that were previously transfected with dCas9-
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VP64 to activate the promoter and later induce overexpression
of the selected gene. Transduction with gRNAs was per-
formed and selection was done with zeocin (no. R25005,
Thermo Fisher Scientific). Confirmation of overexpression
of YKL-40 in D492 and D492M was done by qRT-PCR,
WB, and IF.
Statistical analysis One-way analysis of variance (ANOVA)
using Dunnett’s multiple comparison test or unpaired t tests
were performed using GraphPad Prism to test significance. P
values below 0.05 were considered significant (*p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
Results
Phenotypic and functional characterization of D492M and
D492HER2 D492M and D492HER2 are isogenic cell lines
that share a partial-EMT phenotype but are different in
terms of their ability to form tumors in mice (Sigurdsson
et al. 2011; Ingthorsson et al. 2015). D492M and
D492HER2 are both derived from D492, a breast epithe-
lial progenitor cell line, through endothelial-induced EMT
and oncogene-induced EMT, respectively (Fig. 1a).
D492M and D492HER2 have lost the expression of epi-
thelial markers like E-cadherin, CK14, and CK19 and
gained expression of some mesenchymal markers like
vimentin and Axl, (Fig. 1b). MicroRNAs (miRs) such as
miR-200c, miR-203, and miR-205 are frequently down-
regulated in epithelial cells undergoing EMT, and this was
the case for D492M and D492HER2. While D492 showed
high expression of miR-200c, miR-203, and miR-205,
these microRNAs were greatly reduced in D492HER2
and relatively absent in D492M (Fig. 1c). The difference
in expression levels between D492M and D492HER2
may have been due to a more intermediate state of EMT
for D492HER2. This intermediate state was also support-
ed by the glucose metabolism (Fig. S1). These data show
D492HER2 is more comparable in glucose uptake to
D492 than D492M.
Further characterization demonstrated functional differ-
ences between the cell lines. Notably, D492HER2 cells mi-
grated and invaded through transwell filters more efficiently
than both D492M and D492 (Fig. 1d). The cell proliferation
rate of D492HER2 cells was also significantly higher than in
D492 and D492M cells (Fig. 1e, f). Furthermore, D492HER2
cells were more susceptible to chemically induced apoptosis
than D492 and D492M cells (Fig. 1g), despite an apparent
shift from oxidative phosphorylation to glycolysis as
D492HER2 had higher glucose consumption and higher lac-
tate production than either D492 or D492M cells (Fig. S1).
The functional differences between D492M and
D492HER2 in terms of tumorigenicity prompted us to look
into gene expression and secretome of D492M and
D492HER2 to search for potential candidates responsible for
these effects.
Transcriptome and secretome analyses show that YKL-40 is
enriched in D492HER2 Next, we employed genome-wide
analysis to reveal differences in gene expression in
D492M and D492HER2. More than 40,000 transcripts
were differentially expressed between D492M and
D492HER2 and the most 15 differentially regulated genes
were confirmed by qPCR (Fig. 2a). As expected, HER2
(ErbB2) has much higher expression in D492HER2 cells
due to the ectopic overexpression of the gene (Ingthorsson
et al. 2015). Although CITED1 was the first validated
candidate, its absolute level of expression was low; thus,
we focused our interest on a gene very highly expressed
in D492HER2 compared to D492M (and also to D492),
namely YKL-40 (also known as CHI3L1). The function
of YKL-40 is not clearly understood but it has been sug-
gested to be involved in cancer progression and other
inflammation diseases (Libreros et al. 2012; Libreros
and Iragavarapu-Charyulu 2015; Cohen et al. 2017) and
even in EMT (Jefri et al. 2015).
Genes differentially expressed within the range of two fold
change between D492M and D492HER2 were further classi-
fied using PANTHER analysis (Mi et al. 2013) in order to
establish the biological processes that were enriched in each
cell line. Genes more highly expressed in D492HER2 com-
pared to D492M were shown to be involved in the following
biological processes: D-aspartate transport, inflammatory re-
sponse, cell chemotaxis, cellular response to cytokine stimu-
lus, defense response, cellular response to cytokine stimulus,
cell proliferation, and organic anion transport, among others
(Fig. 2b). Interestingly, YKL-40 was found enriched in four of
the 18 groups, as highlighted in yellow in Fig. 2b.
Complementing the gene expression data, we also mea-
sured by mass spectrometry the secretion of the proteins by
D492M and D492HER2. Analysis of the total secreted
Figure 3. YKL-40 affects migration and invasion in D492 cell lines. a
YKL-40 is more highly expressed in D492HER2, compared to D492 and
D492M, both at mRNA and protein level. b, c Transient siRNA knock-
down of YKL40 reduced the ability of D492HER2 to migrate and invade
in vitro (mean ± SD, n = 3). Statistical significance was tested using one-
way analysis of variance (ANOVA) and Dunnett’s multiple comparison
test (**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). d, e Knock-down of
YKL-40 in D492HER2 in stable cell lines generated by CRISPR/Cas9
technology reduced the ability of D492HER2 to migrate and invade sim-
ilarly to transient transfection. f, g Accordingly, overexpression of
YKL40 in D492 and D492M using CRISPRa system increased their
ability to migrate and invade. Overexpression of YKL-40 was confirmed
by immunofluorescence staining (Scale bar = 100 μm) and western blot-
ting. Migration and invasion assay results are shown as average of eight
replicates (mean ± SD). Unpaired t test was used to test significance
(**p ≤0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
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proteins in the conditioned media (CM) from D492M and
D492HER2 revealed YKL-40 was found in much higher con-
centration in CM from D492HER2 (97.8 LFQ intensity) than
D492M (5.4 LFQ intensity) (Fig. 2c). After these promising
results, we strengthened our focus on YKL-40 as a firm
candidate that could lead to differences between D492M and
D492HER2.
Knockdown of YKL-40 in D492HER2 inhibits migration and
invasion To explore the functional role of YKL-40 in
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D492HER2, we did both transient and stable knockdown
(KD). First, we confirmed the expression of YKL-40 at
mRNA and protein level in D492, D492M, and D492HER2
demonstrating its abundant expression in D492HER2
(Fig. 3a). Transient knockdown with two different siRNAs
greatly reduced YKL-40 expression in D492HER2 cells
(Fig. 3b) and resulted in a significant decrease in migration
and invasion (Fig. 3c). To further corroborate these effects, we
generated stable YKL-40 KD using CRISPR technology in
D492HER2 cells (Fig. 3d). Similar to transient KD of YKL-
40, the stable KD cell line showed a reduction in migration
and invasion compared to control D492HER2 cells (Fig. 3e).
To analyze if overexpression of YKL-40 in D492 and D492M
resulted in increased migration and invasion, we stably
overexpressed YKL-40 in these cells and, indeed, this resulted
in a large increase in both migration and invasion (Fig. 3f, g).
No differences were seen with regard to cell proliferation re-
gardless if YKL-40 was knocked down in D492HER2 or
overexpressed in D492/D492M (data not shown).
Collectively, these results demonstrate that in our cell system,
YKL-40 increases migration and invasion.
YKL-40 expression in D492HER2 is linked to vascular network
formation YKL-40 has previously been linked to angiogenesis
(Shao et al. 2009, 2011). In order to see if increased expression of
YKL-40 in D492HER2 was linked to increased potential to
stimulate angiogenesis in an in vitro assay, we treated
HUVECs on top of Matrigel with CM from D492HER2 with
and without a functional blocking antibody against YKL-40
(mAYKL40). Blocking YKL-40 directly reduced the ability of
CMmedium to induceHUVECs to form capillary-like networks.
This blocking effect was reversed by adding recombinant YKL-
40 protein (YKL-40r) (Fig. 4a).
In agreement, CM from D492 and D492M stably overex-
pressing YKL-40 increased HUVEC network formation on top
of Matrigel, whereas stable knockdown of YKL-40 in
D492HER2 cells reduced HUVECs network formation (Fig.
4b). Additionally, the reduction of YKL-40 in the stable cell line
revealed reduced expression of other pro-angiogenic genes, like
VEGF-A and VEGF-C (Fig. 4c), suggesting a synergic pro-
angiogenic effect induced in D492HER2. Furthermore, adding
recombinant YKL-40 protein (YKL-40r) to media not only stim-
ulated tube formation on endothelial cells, but also increased
proliferation rates of HUVECs (Fig. 4d).
YKL-40 affects phenotype of D492 cell lines when cultured in
3D cultureWhen YKL-40 was downregulated in D492HER2
by transient or stable transfection, no phenotypic changes
were seen in monolayer culture and EMT markers in immu-
nostaining and western blot did not show any differences;
thus, the EMT phenotype remained unaltered in 2D. Due to
the transient nature of using siRNA, it was difficult to explore
if there were any phenotypic changes occurring in 3D culture.
In contrast, 3D culturing of cells with stable knockdown of
YKL-40 revealed differences in phenotype of the D492 cell
lines.
In 3D culture, D492HER2 formed two colony shapes,
spindle-like and grape-like (Ingthorsson et al. 2015).
Interestingly, when YKL-40 was knocked down, there was a
dramatic change in the proportion of spindle-like and grape-
like structures, with the proportion of grape-like structures being
reduced from 21.4% to 1% (Fig. 5a). This subsequent change
in the 3D phenotype of D492HER2 cells with knockdown
of YKL-40 was similar to D492M cells that only showed a
spindle-like phenotype (Sigurdsson et al. 2011). However,
when the recombinant YKL-40 protein (YKL-40r) was
added to the media of D492HER2 with YKL-40 KD, the
grape-like structures were rescued to 32.8% of the total 3D
structures (Fig. 5a).
To confirm the shift to grape-like structures with the addi-
tion of YKL-40, D492M cells overexpressing YKL-40 were
seeded in 3D cell culture. Remarkably, the entire cell popula-
tion lost the ability to form spindle-like structures, and instead
only grape-like structures were observed (Fig. 5b).
Discussion
In this study, we compared phenotypic and functional differ-
ences between two isogenic cell lines that share a partial-EMT
phenotype but differ in terms of oncogenic properties. D492M
is non-tumorigenic, whereas D492HER2 is tumorigenic. We
identified YKL-40, also known as a chitinase-3-like protein 1
(CHI3L1), as a protein highly expressed and secreted in
D492HER2 compared to D492M. Functional in vitro studies
demonstrated that YKL-40 is involved in migration and inva-
sion of D492HER2. Furthermore, blocking YKL-40 in condi-
tionedmedia (CM) fromD492HER2 reduced the ability of the
Figure 4. YKL-40 expression in D492HER2 is linked to increased
potential to stimulate angiogenesis. (a) Conditioned media (CM) from
D492HER2 cells stimulates angiogenesis in an in vitro angiogenesis as-
say. This effect was abrogated upon YKL-40 neutralization by a mono-
clonal antibody (mAYKL40) but rescued by the addition of recombinant
YKL-40 protein (YKL40r) (Scalebar = 200 μm). (i) Parameters of angio-
genesis were measured and analyzed by ImageJ angiogenesis analyzer
plug (mean ± SD) and significance was assessed with one-way analysis of
variance (ANOVA) and Tukey’s multiple comparison test (*p ≤ 0.05). (ii)
Decreased concentration of YKL-40 upon incubation of cells with
mAYKL40 was verified with ELISA. Significance was tested with an un-
paired t-test (****p ≤ 0.0001). (b) When YKL-40 was overexpressed in
D492 and D492M, there was an increase in the capillary network forma-
tion, whereas stable knockdown of YKL-40 in D492HER2 showed a
tendency to reduced capillary network formation. (c) Knockdown of
YKL-40 reduced the expression of other pro-angiogenic inducers,
VEGFA and VEGFC. (d) Finally, recombinant YKL-40 protein (YKL-
40r) induced proliferation of endothelial cells when added to the media.
Unpaired t test was used to test significance (**p ≤ 0.01, ***p ≤ 0.001).
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D492HER2-derived CM to induce formation of capillary like
network in an in vitro angiogenesis assay, which conversely
can be rescued with the addition of recombinant YKL-40 pro-
tein. Finally, KD of YKL-40 in D492HER2 changed the ratio
of spindle- and grape-like structures in favor of spindle-like
structures, which could be reverted when the recombinant
protein was added to the KD cells in 3D culture.
The term EMT is used for describing phenotypic chang-
es where epithelial cells lose and gain epithelial and mes-
enchymal traits, respectively. Very rarely, a complete EMT
occurs, and rather intermediate states are the most frequent
phenotypes. Thus, it is common that traces of epithelial
traits remain and a full mesenchymal phenotype is often
incomplete resulting in a large spectrum of EMT pheno-
types (Nieto 2013).
D492M and D492HER2 share some EMT properties
such as loss of E-cadherin and cytokeratins and formation
of a spindle-shaped phenotype in monolayer. D492M has
a more fixed EMT phenotype with low or absent expres-
sion of epithelial markers, including microRNAs, and
gain of mesenchymal markers (Sigurdsson et al. 2011;
Hilmarsdottir et al . 2015). In a recent paper, we
demonstrated that reintroduction of miR-200c-141 into
D492M was sufficient to revert the phenotype to epithe-
lial lineage, albeit only to luminal epithelial cells. Further
studies demonstrated that the basal cell transcription fac-
tor P63 was necessary to recover the basal/myoepithelial
phenotype. Co-transfection of miR-200c-141 and P63 into
D492M was sufficient to regain the original phenotype of
D492 (Hilmarsdottir et al. 2015). On the other hand,
D492HER2 shows more intermediate EMT phenotype
than D492M and could be defined as a cell line with
partial-EMT (Ingthorsson et al. 2015). Even though
D492HER2 migrates, invades, and proliferates more, it
is more susceptible to apoptosis, its glucose metabolism
is more similar to the one in the epithelial cell line
(D492), and the expression levels of the regulatory epi-
thelial miRNAs are reduced but not as dramatic as in the
case of D492M. Moreover, there are evident phenotypic
differences between these two cell lines when cultured in
3D in reconstituted basement membrane matrix, as
D492M forms exclusively spindle-shaped EMT-like colo-
nies in contrast to D492HER2 that forms mixture of
spindle-shape and grape-like colonies.
Figure 5. YKL-40 affects the phenotype of D492 cell lines in 3D. a
CRISPR/Cas9-mediated knockdown of YKL-40 in D492HER2 cells,
increased the number of spindle-like structures in a 3D culture, but
grape-like structures were recovered with addition of recombinant
YKL-40 protein (YKL40r) to the media (Scalebar = 200 μm). b
Overexpression of YKL-40 in D492M shifted the phenotype from
spindle-like structures to grape-like structures in 3D (Scalebar = 200 μm).
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Triple-negative breast cancer cell lines are often spindle-
shaped with more prominent EMT phenotype in 3D rBM
while cell lines with high HER2 expression are associated
with grape-like phenotype (Han et al. 2010). We have previ-
ously shown that D492M and D492HER2 form spindle-
shaped and grape-like structures in 3D rBM, respectively
(Sigurdsson et al. 2011; Ingthorsson et al. 2016). That over-
expression of YKL-40 in D492M shifts the phenotype toward
grape-like structures may indicate that YKL-40 confers in-
creased plasticity to D492M. Further studies in our laboratory
aim to unravel whether YKL-40 expression is associated with
tumorigenic potential of D492M and D492HER2.
Comparing and analyzing gene-wide expression and
protein-wide secretion of D492M and D492HER2, YKL-40
was the most relevant candidate to study the differences be-
tween the cell lines. YKL-40 is a secreted glycoprotein of a
still unclear function. The protein belongs to the chitinase
family, but it lacks hydrolase activity (Renkema et al. 1998).
It is expressed by several cell types including macrophages,
neutrophils, epithelial cells, synovial cells, chondrocytes,
smooth muscle cells, and some cancer cells (Recklies et al.
2002; Johansen et al. 2006). It is suggested to be involved in
inflammation and angiogenesis, as well as survival and
growth in tumors (Johansen et al. 2006). It is highly secreted
in inflammation diseases (Roslind and Johansen 2009;
Bonneh-Barkay et al. 2010) and some cancers, such as breast
cancer, melanoma, glioblastoma, or small cell lung carcinoma
(Johansen et al. 2006; Shao et al. 2011; Jefri et al. 2015;
Libreros and Iragavarapu-Charyulu 2015). Recently, it has
been linked to idiopathic pulmonary fibrosis (Zhou et al.
2014) and immunosuppressive effects by cancer-associated
fibroblasts in breast cancer (Cohen et al. 2017).
We have confirmed here that changes in intrinsic expression
of YKL-40 in D492HER2 lead to differences in migration and
invasion behavior of the cells. When YKL-40 is downregulated
by transient or stable knockdown, D492HER2 becomes less
migrative and invasive. Migration and invasion are important
processes that support cancer development and progression
(Hanahan and Weinberg 2011) what indicates that YKL-40
may play a key role in invasiveness and dissemination of cancer
cells.
YKL-40 has been previously linked to EMT in non-
small cell lung cancer (Jefri et al. 2015), yet in our study,
when YKL-40 was downregulated in D492HER2, its
EMT phenotype in monolayer remained unaltered and
there were no differences in expression of EMT markers.
Nevertheless, high expression of YKL-40 or the addition
of the recombinant protein has been related to an increase
in the grape-shaped colonies in 3D cell cultures of the
EMT-derived cell lines. This fact suggests that YKL-40
may have been involved in the plasticity of the cells, as
the phenotype in 3D was changed when its expression
was reduced in D492HER2 and then rescued when the
recombinant protein was added. This is also interesting,
since the grape-like structures are often associated with
HER2-expressing cell lines (Kenny et al. 2007).
A number of papers have shown association between YKL-
40 andHER2 expression in breast cancer.Wang et al. showed by
meta-analysis of existing databases that YKL-40 is associated
with poor prognosis in breast cancer patients (Wan et al. 2017).
Kang et al. have demonstrated that YKL-40 expression in breast
cancer is associated with Her-2 and basal-like molecular subtype
of breast cancer (Kang et al. 2014). Also, Shao et al. showed an
association between YKL-40 and Her2 subtype (Shao et al.
2011). Although, the association between YKL-40 and HER2
has been demonstrated, it is, however, to our best knowledge,
still not clear if there are any direct or indirect molecular interac-
tions between these two proteins in breast cancer. Using the
breast mark database (Madden et al. 2013), we were however
not able to link high or low expression of CHI3L1 in distinct
subtype of breast cancer to increased or reduced survival.
PANTHER classification of the differentially regulated
genes showed that YKL-40 is in enriched in biological pro-
cesses related to interactions with the microenvironment that
can support the development of tumors by cancer cells (in-
flammatory response, cell chemotaxis, cellular response to
cytokine stimulus, and defense response). We demonstrate
here that YKL-40 interacts with the microenvironment and
more concretely is contributing to the angiogenesis-inducing
effect of D492HER2.
We have demonstrated that YKL-40 secreted by D492HER2
has a role in angiogenesis. When YKL-40 protein is reduced in
the media by a specific YKL-40 blocking antibody or stable
knockdown in D492HER2, angiogenesis is decreased.
Conversely, increased levels of YKL-40 in the CM by the
addition of recombinant YKL-40 protein or secreted by the
cell line reverted the effects to standard tube formation
parameters.
Interestingly, the reduction of YKL-40 in D492HER2
by the stable knockdown cell line revealed the reduction
of the expression of other pro-angiogenic genes, includ-
ing VEGF-A and VEGF-C. These genes encode protein
ligands that bind and activate VEGF receptor 2
(VEGFR2, Flk-1/KDR), one of the main receptors impli-
cated in the induction of angiogenesis in endothelial cells
(Carmeliet and Jain 2000; Harper and Bates 2008).
Indeed, it has been shown that a monoclonal antibody
against YKL-40 abolishes YKL-40-induced activation
of the membrane VEGF receptor 2 and intracellular sig-
naling mitogen-activated protein (MAP) kinase extracel-
lular signal-regulated kinase (Erk) 1 and Erk 2 (Faibish
et al. 2011).
However, the role of YKL-40 in cancer progression may
not be exclusively derived from cancer cells and not limited to
promote interactions with endothelial cells. Recently, it has
been described that YKL-40 is highly secreted by fibroblasts
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associated to cancer (CAFs) in breast-promoting tumor
growth and facilitating metastasis. Moreover, YKL-40 re-
leased by CAFs supports recruitment of macrophages and
promotes the switch to tumor-associated macrophages
(TAMs) (Cohen et al. 2017). Furthermore, TAMs in breast
cancer express YKL-40 where the secreted protein increases
inflammation and angiogenesis leading to a worse prognosis
and conceivably to metastasis (Shao 2013). Collectively, this
suggests that YKL-40 has a complex role in malignancy that
may provide the signals for further progression involving
changes within cancer cells to migrate and invade and interact
with cells of the surrounding stroma. Moreover, it also may
provide feedback from the microenvironment to support can-
cer development, tumor growth, and incrementation of dis-
semination of cancer cells in metastasis.
Conclusion
In conclusion, our data suggest that YKL-40 may provide
D492HER2 with increased aggressiveness, evidenced by en-
hanced migration and invasion. Furthermore, YKL-40 may
also support cancer progression by facilitating angiogenesis
and may therefore be of interest as a potential novel therapeu-
tic target in HER2-positive breast cancer.
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